Chatzikonstantinou, Thomas http://orcid.org/0000-0003-4105-1253
Kapetanakis, Anargyros
Scarfò, Lydia
Karakatsoulis, Georgios
Allsup, David http://orcid.org/0000-0001-6159-6109
Cabrero, Alejandro Alonso
Andres, Martin http://orcid.org/0000-0001-9891-2988
Antic, Darko
Baile, Mónica
Baliakas, Panagiotis
Bron, Dominique
Capasso, Antonella
Chatzileontiadou, Sofia
Cordoba, Raul
Correa, Juan-Gonzalo
Cuéllar-García, Carolina
De Paoli, Lorenzo
De Paolis, Maria Rosaria
Del Poeta, Giovanni
Demosthenous, Christos
Dimou, Maria http://orcid.org/0000-0001-8197-9895
Donaldson, David
Doubek, Michael http://orcid.org/0000-0002-1269-6282
Efstathopoulou, Maria
Eichhorst, Barbara
El-Ashwah, Shaimaa
Enrico, Alicia http://orcid.org/0000-0002-1983-6145
Espinet, Blanca http://orcid.org/0000-0002-4294-8145
Farina, Lucia
Ferrari, Angela
Foglietta, Myriam
Frederiksen, Henrik http://orcid.org/0000-0001-8905-0220
Fürstenau, Moritz http://orcid.org/0000-0002-6593-0140
García-Marco, José A. http://orcid.org/0000-0002-8993-5982
García-Serra, Rocío http://orcid.org/0000-0003-4857-1016
Gentile, Massimo
Gimeno, Eva
Glenthøj, Andreas
Gomes da Silva, Maria
Gutwein, Odit
Hakobyan, Yervand K. http://orcid.org/0000-0002-9074-7831
Herishanu, Yair
Hernández-Rivas, José Ángel http://orcid.org/0000-0003-4550-757X
Herold, Tobias http://orcid.org/0000-0002-9615-9432
Innocenti, Idanna
Itchaki, Gilad
Jaksic, Ozren
Janssens, Ann
Kalashnikova, Оlga B. http://orcid.org/0000-0002-1856-1055
Kalicińska, Elżbieta
Karlsson, Linda Katharina http://orcid.org/0000-0003-3317-7550
Kater, Arnon P.
Kersting, Sabina
Labrador, Jorge http://orcid.org/0000-0002-3696-0287
Lad, Deepesh http://orcid.org/0000-0003-3754-7774
Laurenti, Luca
Levin, Mark-David http://orcid.org/0000-0003-2139-3547
Lista, Enrico
Lopez-Garcia, Alberto http://orcid.org/0000-0002-5354-5261
Malerba, Lara
Marasca, Roberto http://orcid.org/0000-0002-6431-6878
Marchetti, Monia http://orcid.org/0000-0001-7615-0572
Marquet, Juan
Mattsson, Mattias
Mauro, Francesca R.
Milosevic, Ivana
Mirás, Fatima
Morawska, Marta
Motta, Marina
Munir, Talha
Murru, Roberta
Niemann, Carsten U. http://orcid.org/0000-0001-9880-5242
Rodrigues, Raquel Nunes
Olivieri, Jacopo
Orsucci, Lorella
Papaioannou, Maria
Pavlovsky, Miguel Arturo
Piskunova, Inga
Popov, Viola Maria http://orcid.org/0000-0002-1200-379X
Quaglia, Francesca Maria http://orcid.org/0000-0003-4347-3775
Quaresmini, Giulia http://orcid.org/0000-0002-0993-9693
Qvist, Kristian
Reda, Gianluigi http://orcid.org/0000-0003-4687-7089
Rigolin, Gian Matteo http://orcid.org/0000-0002-8370-5190
Ruchlemer, Rosa
Saghumyan, Gevorg
Shrestha, Amit
Šimkovič, Martin
Špaček, Martin
Sportoletti, Paolo
Stanca, Oana
Stavroyianni, Niki
Tadmor, Tamar http://orcid.org/0000-0002-3435-8612
Te Raa, Doreen
Tonino, Sanne H.
Trentin, Livio http://orcid.org/0000-0003-1222-6149
Van Der Spek, Ellen
van Gelder, Michel
van Kampen, Roel
Varettoni, Marzia
Visentin, Andrea
Vitale, Candida http://orcid.org/0000-0002-2592-8724
Wasik-Szczepanek, Ewa
Wróbel, Tomasz
San Segundo, Lucrecia Yáñez
Yassin, Mohamed
Coscia, Marta
Rambaldi, Alessandro
Montserrat, Emili
Foà, Robin http://orcid.org/0000-0002-5021-3026
Cuneo, Antonio
Stamatopoulos, Kostas http://orcid.org/0000-0001-8529-640X
Ghia, Paolo http://orcid.org/0000-0003-3750-7342
Article History
Received: 28 July 2021
Revised: 29 September 2021
Accepted: 5 October 2021
First Online: 1 November 2021
Competing interests
: LS received advisory boards fees from AbbVie and Janssen; educational activity AstraZeneca. DAl received funding to attend symposia from Gilead and Bayer. MA received advisory boards fees from AbbVie, AstraZeneca, and Janssen-Cilag; travel support from AbbVie, and Novartis. DAn received honoraria from AbbVie, Janssen, and Roche. PB has received honoraria from Abbvie, Gilead and Janssen and research funding from Gilead. RC received speaker fees from Roche, Janssen, AbbVie, AstraZeneca, Celgene, BMS, Kite, and Takeda; received advisory board fees from Janssen, AbbVie, Celgene, BMS, Kite, Takeda, Incyte, Kyowa-Kirin, and ADCT; received travel and accommodation expenses from Roche, Janssen, AbbVie, Celgene, BMS, Kite, Takeda, and Pfizer; research grant from Pfizer. MD received honoraria for advisory board and research support from AstraZeneca, AbbVie, Roche, Gilead, and Janssen. BEi received consulting or advisory boards fees from Janssen, Roche, Novartis, AbbVie, Gilead, Celgene, ArQule, AstraZeneca, Oxford Biomedica (UK), and BeiGene; speaker/speaker’s bureau fees from Janssen, Gilead, Roche, AbbVie, Novartis, Celgene, Adaptive Biotechnologies, BioGene, and AstraZeneca; research support/research funding from Janssen, Gilead, Roche, AbbVie, BeiGene, and AstraZeneca; travel, accommodations, expenses from Janssen, Roche, Novartis, AbbVie, Gilead, and Celgene. MF received honoraria from Janssen and Gilead. JAG-M received honoraria for advisory board and speaker´s bureau from Mundipharma, Glaxo, AbbVie, Roche, Gilead, AstraZeneca, and Janssen; research support from Hoffman-La Roche, AbbVie, and Janssen. RG-S received educational grants from AbbVie, Janssen, and Novartis. EG received travel grants, honoraria as a consultant and/or speaker bureau for Janssen-Cilag, Roche, and AbbVie. MGDS received honoraria for consultancy/advisory boards with Roche, Janssen Cilag, Gilead, AbbVie, and BMS; research Grant from Gilead. YH received honoraria from AbbVie, Janssen, AstraZeneca, and Roche, outside the submitted work. JAH-R received honoraria and advisory boards fees from Janssen, AbbVie, AstraZeneca, Roche, Beigene, Gilead, and BMS-Celgene. OJ received honoraria from AbbVie, Janssen, and Roche. APK received honoraria from Janssen, BMS, AstraZeneca, Roche/Genentech; research money from Janssen, BMS, AstraZeneca, and Roche/Genentech. SK received Travel grant from Celgene; received research funding from Janssen and AbbVie. LL received honoraria from Roche, AbbVie, Janssen, and AstraZeneca. M-DL received travel expenses and advisory board compensation from Janssen, AbbVie, and Roche. AL-G received speaker’s bureau fees from Roche, Janssen, AbbVie, Celgene, Fresenius, Novonordisk; received advisory board participation fees from Janssen, and AbbVie; received travel and accommodation expenses from Roche, Janssen, and AbbVie. MMar received speaker bureau (invited speech) fees from Amgen; received honoraria as a consultant from Gilead. JM received honoraria and travel grants from AbbVie, Janssen, Roche, Gilead, and Takeda. MMat received research grant from GILEAD. FRM received research funding from Gilead; received advisory board participation fees from AbbVie, Gilead, Janssen, AstraZeneca, Takeda, and Roche; received speakers bureau fees from Gilead, Janssen, and AbbVie. TM received honoraria from AbbVie, Janssen, AstraZeneca, Gilead, Roche, and Alexion; received advisory board participation fees from AbbVie, AstraZeneca, Janssen, Alexion, Morphosys, and Sunesis. RM received honoraria from Janssen, and AbbVie. CUN received research funding and/or consultancy fees from AbbVie, AstraZeneca, Janssen, CSL Behring, and Takeda. MAP received advisory board participation fees from Janssen, AbbVie, AstraZeneca, and Merck; received speaker’s bureau fees from Janssen, AbbVie, AstraZeneca, Varifarma, and Merck. FMQ received advisory board participation fees from AstraZeneca and Janssen; received speakers bureau fees from Janssen. GR received consultancy fees and honoraria from AbbVie, AstraZeneca, and Janssen. GMR received honoraria from AbbVie, Gilead, and Janssen; received research funding from Gilead. MŠi received consultancy fees, advisory board participation fees, travel grants, and honoraria from Janssen, Gilead, Roche, AstraZeneca, and AbbVie. MŠp received honoraria from AbbVie, AstraZeneca, Gilead, Janssen, and Roche. PS received funding from Gilead; received advisory board participation fees from AbbVie and Janssen; received honorarium AbbVie, Janssen, and AstraZeneca. LT received advisory board participation fees from Janssen, Roche, AbbVie, Gilead, Takeda; research funding from Janssen, Roche, Takeda, and Gilead. EVDS participated in teaching activities for Amgen. MV received advisory board participation fees from Janssen, Roche, AstraZeneca; received travel expenses from Janssen and AbbVie. AV received speaker’s bureau fees from Italfarmaco and Gilead; received advisory board participation fees from Janssen and Takeda. CV received honoraria from Janssen. TW received research funding from Roche; received honoraria for advisory board, and research funding from Janssen; received honoraria, advisory board participation fees, and travel grant from AbbVie; received speaker’s bureau fees from Gilead. LYSS received advisory board participation fees from Gilead-Kite, Janssen, AbbVie, AstraZeneca, Beigene, Roche, Pfizer, Jazz, BMS, and Merck; received speaker’s bureau fees from Janssen, AbbVie, AstraZeneca, Gilead-Kite, Roche, Pfizer, and Merck. MC received honoraria from AbbVie, Gilead, Janssen, and AstraZeneca. AC received speaker’s bureau and advisory board fees from AbbVie, AstraZeneca, Gilead, and Janssen. RF received speaker’s bureau fees and/or advisory board participation fees from Amgen, Incyte, Janssen, Pfizer, AbbVie, Novartis, Servier, AstraZeneca, ACu received speaker’s bureau fees and advisory board participation fees from Abbvie, Asta-Zeneca, Gilead, Janssen KS received honoraria and research support from Janssen, Abbvie, AstraZeneca, Gilead. PG received honoraria from AbbVie, Arqule/MSD, AstraZeneca, Celgene/Juno/BMS, Janssen, Loxo/Lilly, Roche; Research support, AbbVie, AstraZeneca, Janssen, Gilead, Sunesis. TC, AK, GK, AAC, MB, DB, ACa, SC, J-GC, CC-G, LDP, MRDP, GDP, CD, MDi, DD, ME, SE-A, AE, BEs, LF, AF, HF, MFü, MG, AG, OG, YKH, TH, II, GI, AJ, OBK, EK, LKK, JL, DL, EL, LM, RM, IM, FM, MMor, MMot, RNR, JO, LO, MP, IP, VMP, GQ, KQ, RR, GS, AS, OS, NS, TT, DTR, SHT, MVG, RVK, EWS, MY, AR, EM have no conflict of interest to disclose.